Systems and Methods for Prostate Treatment

• US 20100286679A1
• Filed: 04/27/2010
• Published: 11/11/2010
• Est. Priority Date: 04/27/2009
• Status: Active Grant

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: NxThera, Inc (Boston Scientific Corporation)
• Inventors: Shadduck, John H., Hoey, Michael
• Granted Patent: US 9,833,277 B2
• Time in Patent Office: Days
• US Class Current: 606/27
• CPC Class Codes: A61B 18/04 by heating by applying electromagnetic radiation A61B18/18; hyperthermia using electric or magnetic fields, radiation or ultrasound A61N
• CPC Class Codes: A61B 2018/00017 with gas
• CPC Class Codes: A61B 2018/00029 open
• CPC Class Codes: A61B 2018/00547 Prostate
• CPC Class Codes: A61B 2018/00577 Ablation
• CPC Class Codes: A61B 2018/1425 Needle
• CPC Class Codes: A61B 2218/005 using gas or vapor, e.g. for protection or purging

Abstract

An energy delivery probe is provided that may include any of a number of features. One feature of the energy delivery probe is that it can apply energy to tissue, such as a prostrate, to shrink, damage, denaturate the prostate. In some embodiments, the energy can be applied with a vapor media. The energy delivery probe can include a vapor delivery member configured to extend into a transition zone prostate tissue. A condensable vapor media can be delivered from the vapor delivery member into the transition zone tissue, wherein the condensable vapor media can propagate interstitially in the transition zone tissue and be confined in the transition zone tissue by boundary tissue adjacent to the transition zone tissue Methods associated with use of the energy delivery probe are also covered.

Claims

1. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing a vapor delivery member into a transition zone tissue of a prostate; and

injecting a condensable vapor media from the vapor delivery member into the transition zone tissue, wherein the condensable vapor media propagates interstitially in the transition zone tissue and is confined in the transition zone tissue by a boundary tissue adjacent the transition zone tissue.

2. The method of claim 1 wherein the boundary tissue comprises a prostatic urethra.

3. The method of claim 1 wherein the boundary tissue comprises a fibrous plane between lateral lobes of the prostate.

4. The method of claim 1 wherein the boundary tissue comprises a central zone tissue.

5. The method of claim 1 wherein the boundary tissue comprises a fibrous layer between transition zone tissue and a peripheral zone tissue.

6. The method of claim 1 wherein the boundary tissue comprises an anterior fibromuscular stromal tissue.

7. The method of claim 1 wherein the condensable vapor media is injected for an interval of 20 second or less.

8. The method of claim 1 wherein the condensable vapor media is injected at a pressure ranging from about 1 psi to 5 psi.

9. The method of claim 1 wherein the vapor deliver member is introduced transversely relative to a urethra.

10. The method of claim 1 wherein the vapor deliver member is introduced substantially aligned with a urethra.

11. The method of claim 1 wherein the condensable vapor media is injected in a plurality of selected locations in the transition zone tissue.

12. The method of claim 1 wherein the vapor delivery member is introduced into the transition zone tissue through a wall of a urethra from a trans-urethral probe.

13. The method of claim 1 wherein the vapor delivery member is introduced into the transition zone tissue from a trans-rectal probe.

14. The method of claim 1 wherein a pressure of the vapor media introduction is controlled by a computer controller.

15-19. -19. (canceled)

20. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing a vapor delivery member into at least one selected location in transition zone tissue of a prostate; and

injecting a condensable vapor media from the vapor delivery member into the transition zone tissue so as to ablate transition zone tissue adjacent a urethra without ablating transition zone tissue adjacent a fibromuscular stroma.

21. The method of claim 20 wherein the condensable vapor media is injected for an interval of 20 seconds or less.

22. The method of claim 20 wherein the condensable vapor media is injected at a pressure ranging from about 1 psi to 5 psi.

23. The method of claim 20 wherein the vapor deliver member is introduced transversely relative to a urethra.

24. The method of claim 20 wherein the vapor deliver member is introduced substantially aligned with a urethra.

25. The method of claim 20 wherein the condensable vapor media is injected in a plurality of selected locations in the transition zone tissue.

26. The method of claim 20 wherein the vapor delivery member is introduced into the transition zone tissue through a wall of a urethra from a trans-urethral probe.

27. The method of claim 20 wherein the vapor delivery member is introduced into the transition zone tissue from a trans-rectal probe.

28. The method of claim 20 wherein a pressure of the vapor media introduction is controlled by a computer controller.

29. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing an energy delivery member into a transition zone tissue of a prostate; and

delivering energy utilizing convective heating from the energy delivery member into the transition zone tissue, wherein the convective heating is reflected off fibrous bathers surrounding the transition zone tissue so as to confine the energy to the transition zone tissue.